Implementing Cabenuva in Arkansas HIV Programs
Key facts
- Who runs it
- University of Arkansas
- Where
- Little Rock, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 7 Mar 2022
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Home visit delivery strategy
- Record updated
- 3 September 2024
- Why it stopped
- Insufficient enrollment.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Persons, 18-years old and older
- Receiving Cabenuva injections (following registered USPI) at one of the six clinics in this study
- Ability to provide informed consent
- Patients who would receive Cabenuva at home: Living within 40-miles from the three clinics randomized to the at-home arm of the study
Who cannot take part
- Pregnant or breastfeeding women, or women who plan to become pregnant during the study period
Where in United States
- University of Arkansas for Medical SciencesLittle Rock, United States
About the trial
What the trial wants to find out
This study seeks to address this gap by studying two Cabenuva delivery strategies conducted at six outpatient HIV clinics in Arkansas, a Southern state with a large population of rural, poor, and African-American residents. The two delivery strategies are clinic delivery and home delivery. In the clinic delivery study arm patients will receive Cabenuva injections at the clinic (50 patients), and in the home delivery study arm patients will receive the injections at home (50 patients). The study team will follow the patients in both study arms for 10 months. After 5 months, the patients will complete a treatment satisfaction survey, and after 10 months the study team will examine clinic records to assess their medication adherence.
Read full original descriptionShow less
Secondary outcomes will include clinician perceptions of acceptability, feasibility, and appropriateness of Cabenuva delivery strategies. The study team will also collect qualitative data from patients and clinic employees to learn more in depth about their perceptions of Cabenuva, the delivery strategies, their implementation, and barriers and facilitators. Finally, the study team will estimate the costs associated with the two delivery strategies from the clinic and patient perspectives.
The data from this study provide information on what delivery strategies for long acting HIV medications offer best results, how these strategies are perceived by patients and clinicians, and how costly and feasible the strategies are to implement in practice.
The 2 groups in the trial
- Clinic visit armNo study treatment, for comparison
Patient will receive Cabenuva injection at the clinic
- Home visit armTreatment being tested
Patient will receive Cabenuva injection at home
Treatment: Home visit delivery strategy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Implementing Long-Acting Cabotegravir + Rilpivirine in Arkansas Programs Utilizing Out-patient Clinics Versus In-home Visits
- Record updated
- 3 September 2024